How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer

The trimodality approach represented by concurrent chemoradiotherapy followed by surgical resection is a highly effective, but potentially toxic therapy for locally advanced non-small-cell lung cancer (NSCLC). In this review, we discuss the current status of this therapy in patients with mediastinal...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunitoh, H, Suzuki, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359947/
https://www.ncbi.nlm.nih.gov/pubmed/17473830
http://dx.doi.org/10.1038/sj.bjc.6603751
_version_ 1782152926455660544
author Kunitoh, H
Suzuki, K
author_facet Kunitoh, H
Suzuki, K
author_sort Kunitoh, H
collection PubMed
description The trimodality approach represented by concurrent chemoradiotherapy followed by surgical resection is a highly effective, but potentially toxic therapy for locally advanced non-small-cell lung cancer (NSCLC). In this review, we discuss the current status of this therapy in patients with mediastinal node-positive (N2) stage III NSCLC or superior sulcus tumor, and present an overview of the principles for optimisation of the risk/benefit. Numerous clinical questions remain, and enrolment of patients into well-designed clinical trials should be encouraged.
format Text
id pubmed-2359947
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23599472009-09-10 How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer Kunitoh, H Suzuki, K Br J Cancer Review The trimodality approach represented by concurrent chemoradiotherapy followed by surgical resection is a highly effective, but potentially toxic therapy for locally advanced non-small-cell lung cancer (NSCLC). In this review, we discuss the current status of this therapy in patients with mediastinal node-positive (N2) stage III NSCLC or superior sulcus tumor, and present an overview of the principles for optimisation of the risk/benefit. Numerous clinical questions remain, and enrolment of patients into well-designed clinical trials should be encouraged. Nature Publishing Group 2007-05-21 2007-05-01 /pmc/articles/PMC2359947/ /pubmed/17473830 http://dx.doi.org/10.1038/sj.bjc.6603751 Text en Copyright © 2007 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Review
Kunitoh, H
Suzuki, K
How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer
title How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer
title_full How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer
title_fullStr How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer
title_full_unstemmed How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer
title_short How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer
title_sort how to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359947/
https://www.ncbi.nlm.nih.gov/pubmed/17473830
http://dx.doi.org/10.1038/sj.bjc.6603751
work_keys_str_mv AT kunitohh howtoevaluatetheriskbenefitoftrimodalitytherapyinlocallyadvancednonsmallcelllungcancer
AT suzukik howtoevaluatetheriskbenefitoftrimodalitytherapyinlocallyadvancednonsmallcelllungcancer

Ejemplares similares